Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the first proven ERA therapy to show reduction in morbidity and mortality in patients diagnosed with PAH. This presentation covers the pharmacology and key studies of macitentan.